A 2023 analysis of the SUSTAIN and PIONEER trials published in Cardiovascular Diabetology showed significant reductions in high-sensitivity C-reactive protein, a marker of systemic inflammation, among patients taking semaglutide
Apovian, M.D., co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, points out that its tough to compare these trials because they may have differences like how long the subjects are on the drugs
At the pancreas, it potentiates glucose-stimulated insulin secretion while suppressing glucagon release, thereby lowering circulating glucose concentrations
Select Your Tests: Pick the test(s) that align with your health goals (micronutrients, hormones, gut health, or aging)
This same principle applies to other next-generation metabolic peptides like Survodutide and Mazdutide
doi: 10.1136/gutjnl-2021-324243 63